Patient guide · NAD+ IV

NAD+ IV side effects and what a clinic should do.

A practical guide to tolerance, monitoring, escalation and why infusion speed and clinical context matter.

For people searching for NAD+ IV side effects and safety in Bali.

Clinical guide, not a prescriptionReviewed 22 August 2026How this page is governed

Indonesian nurse monitoring a patient during a supervised NAD+ infusion in a Bali villa — Supervised NAD+ care in Bali.

Tolerance can vary

People may experience discomfort during an infusion. Symptoms must be assessed in context rather than dismissed as proof that the treatment is working.

The team needs an action route

A supervised service must be able to slow or stop administration, reassess the patient, document the event and escalate when clinically necessary.

The next dose uses the first response

Dose, duration, tolerance and symptoms belong in the clinical record. A repeat session should not ignore what happened previously.

Connected clinical library

NAD+, from first question to monitored protocol.

Dose, duration, cost, evidence, tolerance and the clinical checks that connect them.

NAD+ therapy in Bali→NAD+ IV dose guide→NAD+ infusion duration→NAD+ cost in Bali→

Direct answers

Questions to resolve before treatment.

Should I continue if I feel unwell during an infusion?

Tell the attending clinician immediately. The clinical team decides whether to slow, stop, assess or escalate; do not self-manage an active IV reaction.

Are side effects proof that NAD+ is working?

No. Symptoms during treatment require clinical assessment and should not be reframed automatically as efficacy.

Evidence position

The evidence is applied to the specific clinical question. It supports an individual assessment; it does not replace diagnosis or guarantee an outcome.

Sources used for this page

Human studyGrant et al.: intravenous NAD+ metabolome pilot (2019) ↗Direct six-hour IV NAD+ administration and measured metabolic changes; a small pilot, not proof of broad clinical benefit.Human studyReal-world IV NAD+ and IV NR tolerability pilot (2026) ↗Exploratory infusion duration, symptoms and short-term biomarkers; retrospective data, not an efficacy trial.Scientific reviewVerdin: NAD+ in ageing, metabolism and neurodegeneration (2015) ↗Established NAD+ biology and mechanistic context; it does not establish outcomes from IV therapy.

Accountability

Who stands behind this clinical information.

01 · Editorial ownership

Clinic Terrain Clinical Editorial Team

Prepared and reviewed on 22 August 2026.

02 · Medical accountability

dr. I Wayan Cahyadi Surya Distira Putra, MPH

Clinic Terrain Chief Physician. He leads the medical interpretation of mechanistic, longevity, NAD+ and peptide pathways. The attending physician retains authority over the final clinical plan for each patient.

Chief Physician profile →

03 · Operating and publication standard

Klinik Pratama Cepat Sehat · Bali

Clinical editorial policy →Evidence library →

Your first message · Where you are + what you need help with

Turn what you have learned into a clear question for the clinical team.

Ask about NAD+ monitoring →WhatsApp intake open 24/7 · One-minute first-response target